{"id":37001,"date":"2026-03-28T10:08:00","date_gmt":"2026-03-28T14:08:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37001"},"modified":"2026-03-08T14:23:57","modified_gmt":"2026-03-08T18:23:57","slug":"get-your-anda-approved-the-generic-manufacturers-complete-checklist-for-timely-fda-approval","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/get-your-anda-approved-the-generic-manufacturers-complete-checklist-for-timely-fda-approval\/","title":{"rendered":"Get Your ANDA Approved: The Generic Manufacturer’s Complete Checklist for Timely FDA Approval"},"content":{"rendered":"\n

A practical guide for regulatory affairs teams, IP counsel, and C-suite decision-makers<\/em><\/p>\n\n\n\n

The Stakes of the First Submission<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Every year, generic drug manufacturers leave hundreds of millions of dollars on the table. Not from bad science. Not from inadequate manufacturing. From avoidable regulatory mistakes that trigger refuse-to-receive decisions, complete response letters, and years of compounding delays.<\/p>\n\n\n\n

The Abbreviated New Drug Application process is, in principle, straightforward. You demonstrate that your product is bioequivalent to a brand-name reference drug, prove you can make it consistently and safely, and show you are not infringing valid patents. In practice, the ANDA pathway is a technical gauntlet where a single missing data element, an ambiguous specification, or a misread Orange Book entry can set a program back eighteen months and cost a mid-size company its market window entirely.<\/p>\n\n\n\n

This guide is a working checklist for regulatory affairs professionals, business development teams, and the legal counsel who support them. It covers the full lifecycle of an ANDA: pre-filing strategy, dossier construction, the GDUFA review clock, patent litigation considerations, and the post-approval compliance burden that many filers underestimate. Where relevant, it references DrugPatentWatch, one of the most widely used tools for tracking pharmaceutical patent expirations and Orange Book listings, which generic manufacturers use to prioritize targets and time their filings.<\/p>\n\n\n\n

The generic drug industry generated approximately $106 billion in U.S. sales in 2023, and generics now account for roughly 90 percent of all U.S. prescriptions dispensed [1]. The economics of winning a first-filer position, or even securing a reliable second wave launch, reward precision over speed. A single day of exclusivity for a blockbuster drug can translate to $5 million or more in incremental revenue. Getting the ANDA right, and getting it right the first time, is not a regulatory nicety. It is a business imperative.<\/p>\n\n\n\n

What the ANDA Process Actually Is<\/h2>\n\n\n\n

The Abbreviated New Drug Application derives its name from the fact that it does not require the applicant to independently establish that the drug is safe and effective. That work was done when the brand-name manufacturer filed the original New Drug Application. The generic applicant instead relies on FDA’s prior finding of safety and efficacy for the reference listed drug (RLD), while demonstrating two things: that its product is pharmaceutically equivalent to the RLD, and that it is bioequivalent.<\/p>\n\n\n\n

Pharmaceutical equivalence means the product contains the same active pharmaceutical ingredient, in the same dosage form, at the same strength, and meets compendial or other applicable standards for identity, strength, quality, and purity. Bioequivalence means that the rate and extent of absorption of the active ingredient are not significantly different from those of the RLD under similar experimental conditions.<\/p>\n\n\n\n

The statutory basis for the ANDA pathway is the Drug Price Competition and Patent Term Restoration Act of 1984, known universally as the Hatch-Waxman Act. Before Hatch-Waxman, generic manufacturers had no streamlined pathway. Every drug required a full NDA regardless of whether a brand-name version already existed. Hatch-Waxman created the modern generic industry by allowing bioequivalence data to substitute for redundant clinical trials, while simultaneously creating the patent certification system that defines the competitive dynamics of generic launches today.<\/p>\n\n\n\n

The Orange Book: Where It All Starts<\/h3>\n\n\n\n

The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, the Orange Book, is the authoritative source for RLD identification, listed patents, and exclusivity information. Every ANDA filer begins by identifying their RLD in the Orange Book and reviewing the patents listed for that product.<\/p>\n\n\n\n

Listed patents fall into two categories in practice: drug substance patents that cover the active moiety, and drug product patents that cover formulation, dosage form, or method of use. Patent terms, including patent term extensions granted under 35 U.S.C. 156, are listed alongside each entry. Exclusivity periods, which are independent of patent protection, are also listed and present a separate barrier to generic approval.<\/p>\n\n\n\n

The Orange Book does not list every patent a brand manufacturer holds on a given drug. It lists only the patents the brand manufacturer has submitted to FDA for listing, and FDA lists them without verifying their validity or relevance. This creates a strategic asymmetry: brand manufacturers have an incentive to list broadly, while generic manufacturers must assess which listed patents are actually enforceable before deciding how to certify.<\/p>\n\n\n\n

This is where tools like DrugPatentWatch become operationally important. DrugPatentWatch aggregates Orange Book data, patent prosecution histories, litigation records, and exclusivity information into a searchable database that allows generic manufacturers to rapidly assess the IP landscape around any given RLD. Understanding which patents are expiring, which are subject to existing Paragraph IV litigation, and which have already been invalidated can determine whether a product is worth pursuing at all.<\/p>\n\n\n\n

The Four Paragraph Certifications<\/h3>\n\n\n\n

The Hatch-Waxman Act requires every ANDA applicant to certify with respect to each patent listed for the RLD. There are four possible certifications:<\/p>\n\n\n\n

    \n
  • Paragraph I: No patent information has been submitted to FDA for the listed drug.<\/li>\n\n\n\n
  • Paragraph II: The patent has expired.<\/li>\n\n\n\n
  • Paragraph III: The date on which the patent expires, with a statement that the generic will not be launched until after expiration.<\/li>\n\n\n\n
  • Paragraph IV: The patent is invalid, unenforceable, or will not be infringed by the generic product.<\/li>\n<\/ul>\n\n\n\n

    Paragraphs I, II, and III are relatively uncomplicated. The applicant either waits for patent expiration or certifies that no relevant patents exist. Paragraph IV is different. It is simultaneously a legal declaration, a business strategy, and a lawsuit trigger. Within 20 days of FDA accepting a Paragraph IV ANDA for filing, the applicant must notify the patent holder and the RLD holder, who then have 45 days to sue for infringement. If they sue, the Hatch-Waxman 30-month stay kicks in, automatically delaying final ANDA approval until the earlier of the stay expiring, a court ruling on patent validity or non-infringement, or the patent expiration.<\/p>\n\n\n\n

    The Patent Landscape Before You File<\/h2>\n\n\n\n

    Patent analysis is not something regulatory affairs teams should do alone, and it is not something IP counsel should do without understanding the commercial context. The most effective ANDA programs integrate regulatory strategy, patent analysis, and business development from the earliest stages of product selection.<\/p>\n\n\n\n

    Paragraph IV Certifications and the 30-Month Stay<\/h3>\n\n\n\n

    The 30-month stay is the single most consequential mechanism in Hatch-Waxman litigation. When a brand manufacturer sues within the 45-day window, FDA cannot grant final approval to the ANDA for 30 months, unless a court resolves the case earlier. This effectively gives brand manufacturers 30 months to litigate patent infringement claims regardless of the underlying merits.<\/p>\n\n\n\n

    The stay applies per NDA holder per listed patent, but the Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA) limited the stay to one 30-month period per ANDA applicant, regardless of how many patents the brand manufacturer lists. Before the MMA, brand manufacturers routinely listed patents sequentially to generate multiple consecutive 30-month stays for each new ANDA, a practice that became known as ‘evergreening.’<\/p>\n\n\n\n

    From a practical standpoint, the 30-month stay means that filing a Paragraph IV ANDA against a drug with multiple listed patents is a multi-year commercial commitment. A regulatory affairs team that treats patent certification as a box-checking exercise rather than a strategic decision will repeatedly find itself waiting out stays on patents that should have been analyzed more carefully before filing.<\/p>\n\n\n\n

    The stay does not prevent FDA from granting tentative approval. Tentative approval confirms that the ANDA would receive final approval once the stay expires, exclusivity periods run, or the patent situation resolves. Tentative approval is particularly important for ANDAs that may benefit from international procurement programs, such as PEPFAR, where FDA approval is a prerequisite.<\/p>\n\n\n\n

    Using DrugPatentWatch to Map the IP Battlefield<\/h3>\n\n\n\n

    Before committing significant resources to bioequivalence studies and CMC development, any serious generic manufacturer should conduct a structured patent landscape analysis. This means more than reading the Orange Book listing. It means understanding the prosecution history of listed patents, tracking existing Paragraph IV litigation and its outcomes, and identifying patents that may be vulnerable to invalidity challenges.<\/p>\n\n\n\n

    DrugPatentWatch provides a consolidated view of patent expirations, litigation history, and patent term extension data that would otherwise require hours of manual searching across USPTO databases, FDA databases, and PACER court records. The platform’s Orange Book tracking features allow teams to set alerts when new patents are listed for a target RLD, which is critical because brand manufacturers sometimes list new patents after generic filers have already done their analysis.<\/p>\n\n\n\n

    A practical landscape analysis should answer four questions before a company commits to an ANDA program: Which listed patents expire before the commercial window the company wants to hit? Which patents have already been challenged and found invalid or not infringed in other ANDA litigation? Which patents, if litigated, present the highest risk of sustaining a 30-month stay? Are there method-of-use patents that could be avoided through a ‘skinny label’ approach?<\/p>\n\n\n\n

    The Skinny Label Strategy<\/h3>\n\n\n\n

    A skinny label, formally called a section viii carve-out, allows an ANDA applicant to omit from its labeling any indication or method of use that is covered by a listed method-of-use patent. The generic product is then approved with a narrower label, and the applicant certifies under section viii that it is not seeking approval for the carved-out use.<\/p>\n\n\n\n

    The skinny label strategy has faced significant legal challenges in recent years. The GlaxoSmithKline v. Teva Pharmaceuticals litigation, which went through multiple rounds of appeals before settling, raised difficult questions about whether generic manufacturers could face induced infringement claims even when using a skinny label, if sufficient evidence suggested that physicians would use the generic product for the patented indication regardless of the label. The Federal Circuit’s decisions in that case created uncertainty that has made some generic filers more cautious about relying on skinny labels.<\/p>\n\n\n\n

    Despite the legal risk, skinny label strategies remain commercially valuable for drugs where the patented method of use accounts for a minority of prescriptions. The regulatory team’s job is to document the carve-out clearly, ensure that all labeling elements for the carved-out indication are genuinely removed, and coordinate with IP counsel on the risk profile before filing.<\/p>\n\n\n\n

    Pre-ANDA Preparation: The Work That Decides Everything<\/h2>\n\n\n\n

    The quality of an ANDA dossier is largely determined before the first page is drafted. Pre-filing preparation, including RLD selection, bioequivalence study design, API sourcing, and formulation development, establishes the factual foundation that regulatory writers later translate into submission content. Deficiencies in the underlying science cannot be corrected by better writing.<\/p>\n\n\n\n

    Reference Listed Drug Selection<\/h3>\n\n\n\n

    The RLD is the brand-name drug to which the generic applicant’s product must be demonstrated as bioequivalent. FDA publishes the Orange Book’s list of approved drug products with RLD designations, and FDA may sometimes change RLD designations, which creates a complication for ANDA applicants mid-program.<\/p>\n\n\n\n

    The choice of RLD is not always obvious. For some drugs, multiple brand-name products exist with different formulations or strengths. For others, the original RLD may have been withdrawn from the market, requiring the applicant to petition FDA for permission to use an alternative reference standard. The ‘withdrawn for reasons of safety or effectiveness’ question matters enormously: if an RLD was withdrawn for safety reasons, FDA will not accept an ANDA referencing it.<\/p>\n\n\n\n

    FDA’s Inactive Ingredient Database and the product-specific guidance documents (PSGDs) published for many drugs provide critical context for formulation choices. PSGDs specify FDA’s current thinking on the appropriate bioequivalence study design, acceptable inactive ingredients, and any special testing requirements. Ignoring PSGDs when they exist is a common mistake that leads to avoidable complete response letters.<\/p>\n\n\n\n

    Bioequivalence Study Design<\/h3>\n\n\n\n

    Bioequivalence studies are the scientific heart of most ANDAs. For systemically absorbed drugs with well-characterized pharmacokinetics, the standard study design is a two-way crossover study in healthy adult subjects, comparing the pharmacokinetic parameters (AUC and Cmax) of the test and reference products. FDA considers products bioequivalent when the 90 percent confidence intervals for both AUC ratio and Cmax ratio fall within the 80 to 125 percent acceptance criteria.<\/p>\n\n\n\n

    The standard design does not fit every drug. Highly variable drugs, defined as those where within-subject variability for Cmax or AUC is 30 percent or greater in a replicate crossover study, present a particular challenge. FDA allows a scaled average bioequivalence approach for highly variable drugs, where the acceptance limits expand based on the reference product’s within-subject variability. This regulatory allowance exists specifically to prevent adequate bioequivalence from being obscured by pharmacokinetic noise.<\/p>\n\n\n\n

    Narrow therapeutic index drugs present the opposite problem. For drugs like warfarin, digoxin, carbamazepine, and lithium, the standard 80 to 125 percent window may be too wide given the clinical consequences of exposure differences. FDA has indicated that tighter bioequivalence criteria, such as 90 to 111 percent, are appropriate for some NTI drugs, and the agency has been inconsistent about when and how to apply them. Any ANDA program targeting an NTI drug should seek FDA guidance through a controlled correspondence before finalizing the study protocol.<\/p>\n\n\n\n

    The Fed\/Fasted Decision<\/h4>\n\n\n\n

    Most oral solid dosage forms require bioequivalence studies in both fed and fasted states, since food can significantly alter drug absorption. The practical question is which condition to use as the primary study and how to handle potential failures in one condition. FDA’s product-specific guidance typically specifies fed, fasted, or both, and the applicant needs to ensure their clinical research organization (CRO) designs the study accordingly.<\/p>\n\n\n\n

    Fed-condition studies require a standardized high-fat, high-calorie meal before dosing. The meal composition is specified in FDA guidance: approximately 150 calories from protein, 250 from carbohydrate, and 500 to 600 from fat. Using a different meal composition invalidates the fed bioequivalence data and requires a repeat study. This detail gets missed more often than it should, particularly when CROs do not have direct familiarity with FDA bioequivalence requirements.<\/p>\n\n\n\n

    Waiver Eligibility: BCS-Based Waivers<\/h4>\n\n\n\n

    For certain oral solid dosage forms, an in vivo bioequivalence study can be waived if the drug substance meets the criteria of the Biopharmaceutics Classification System. A BCS Class I drug, meaning high solubility and high permeability, may qualify for a biowaiver if the formulation also meets additional criteria including rapid dissolution and the absence of excipients known to affect gastrointestinal motility or membrane permeability.<\/p>\n\n\n\n

    FDA expanded BCS waiver eligibility to Class III drugs (high solubility, low permeability) in 2017, though with stricter requirements. The World Health Organization accepts BCS biowaivers for Class III drugs more broadly, which can create complications for manufacturers who develop a formulation using WHO criteria and then attempt to extrapolate to FDA’s requirements for a U.S. ANDA.<\/p>\n\n\n\n

    A biowaiver application requires in vitro dissolution data comparing the test and reference products across three pH conditions (1.2, 4.5, and 6.8), using the same dissolution method. The dissolution profiles must be similar, typically assessed using the f2 similarity factor, which must be 50 or greater. When the f2 test is not applicable due to high dissolution rates, alternative criteria apply.<\/p>\n\n\n\n

    Active Pharmaceutical Ingredient Sourcing and DMFs<\/h3>\n\n\n\n

    The API used in an ANDA must come from a supplier who has either filed a Type II Drug Master File (DMF) with FDA or provided a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines. The DMF route is more common for ANDA filers targeting the U.S. market.<\/p>\n\n\n\n

    A Type II DMF covers the API’s manufacturing process, specifications, and quality controls. The DMF holder files the DMF independently, and the ANDA applicant references the DMF by number in the application. FDA reviews the DMF only in the context of the application referencing it, so DMF quality can delay ANDA approval even when the rest of the application is complete.<\/p>\n\n\n\n

    Verifying the DMF’s status before committing to an API supplier is essential. FDA’s DMF database shows whether a DMF is on file and whether it has received any deficiency letters. A DMF with outstanding deficiencies is a time bomb in an ANDA program. Generic manufacturers should audit their API suppliers’ DMF status annually and require suppliers to notify them immediately if FDA issues a deficiency letter.<\/p>\n\n\n\n

    Sourcing APIs from manufacturers with a strong FDA inspection history, and ideally from facilities that supply multiple high-volume ANDA filers, reduces inspection risk. FDA’s inspection database, accessible through the FDA Establishment Inspection Report system, shows inspection history and the outcome of recent inspections. Any Official Action Indicated classification or Warning Letter in the past three years is a serious red flag for an API supplier.<\/p>\n\n\n\n

    Building the ANDA Dossier: A Section-by-Section Breakdown<\/h2>\n\n\n\n

    The ANDA is submitted in the Common Technical Document format through FDA’s electronic Common Technical Document (eCTD) gateway. The CTD structure organizes the application into five modules, though Module 1 (administrative information) and the content of Module 5 (clinical study reports) differ somewhat for ANDAs compared to NDAs.<\/p>\n\n\n\n

    Module 1: Administrative and Regional Information<\/h3>\n\n\n\n

    Module 1 contains the application form (FDA Form 356h), the cover letter, patent certifications, the signed certification of truth and accuracy, and any environmental assessment or claim of categorical exclusion. The 356h form is the legal document that formally initiates the application and must accurately reflect the dosage forms, strengths, and routes of administration being requested.<\/p>\n\n\n\n

    Patent certifications appear in Module 1 and must address every patent listed in the Orange Book for the RLD at the time of submission. A missed patent certification is an automatic refuse-to-receive finding. Given that brand manufacturers sometimes list patents very close to the submission date, applicants should verify the Orange Book listing on the business day before submission, not the day the dossier is finalized.<\/p>\n\n\n\n

    The cover letter should clearly identify the application type (ANDA), the proposed trade name or the note that no trade name is being proposed, the submission type (original or amendment), the contact information for both regulatory affairs and legal counsel, and any requests for expedited review under GDUFA programs. A disorganized cover letter does not by itself cause a refuse-to-receive decision, but it creates a poor first impression with reviewers and can lead to avoidable back-and-forth during the filing review period.<\/p>\n\n\n\n

    Module 2: Summaries and Overviews<\/h3>\n\n\n\n

    Module 2 contains the quality overall summary (QOS) for chemistry, manufacturing, and controls, as well as the nonclinical and clinical overviews. For a standard ANDA, the clinical overview is relatively brief because the applicant is relying on the RLD’s established safety and efficacy profile. The clinical overview primarily covers the bioequivalence study rationale and any waivers.<\/p>\n\n\n\n

    The quality overall summary, however, is a critical document. It summarizes the CMC information from Module 3 in a way that should allow an experienced reviewer to assess the application’s quality without reading every detail of Module 3. A weak QOS that fails to explain key manufacturing decisions, justify specifications, or address potential risks will generate information requests that slow the review.<\/p>\n\n\n\n

    Module 3: Chemistry, Manufacturing, and Controls<\/h3>\n\n\n\n

    Module 3 is typically the largest and most technically complex part of an ANDA. It covers the drug substance, the drug product, and the container closure system.<\/p>\n\n\n\n

    Drug Substance Section (Module 3.2.S)<\/h4>\n\n\n\n

    The drug substance section covers nomenclature, structure, physicochemical properties, manufacturer information, process controls, characterization data, specifications, analytical methods and validation, reference standards, container closure, and stability.<\/p>\n\n\n\n

    For APIs covered by a referenced DMF, much of this information is in the DMF rather than the ANDA itself. The applicant provides a letter of authorization (LOA) from the DMF holder allowing FDA to cross-reference the DMF, and the ANDA’s drug substance section summarizes the relevant information with pointers to the DMF.<\/p>\n\n\n\n

    Specification setting for the API is a frequent source of deficiencies. FDA expects applicants to justify their specifications based on the development data and, where applicable, set limits that are tighter than compendial limits when the development data support it. Applicants who simply adopt compendial limits without engaging with their batch data often receive comments questioning whether the proposed limits are adequately controlling quality.<\/p>\n\n\n\n

    Drug Product Section (Module 3.2.P)<\/h4>\n\n\n\n

    The drug product section covers the description and composition, the pharmaceutical development rationale, the manufacturing process and controls, excipient controls, container closure, microbiological attributes, and stability.<\/p>\n\n\n\n

    Pharmaceutical development is where the applicant explains the formulation rationale and the relationship between the formulation variables and product performance. For a simple generic tablet, this section can be relatively concise. For a modified-release formulation, a transdermal patch, or a complex suspension, pharmaceutical development is extensive and must demonstrate that the applicant understands the mechanism by which the product achieves its dissolution or absorption profile.<\/p>\n\n\n\n

    The manufacturing process description must be specific enough that FDA can assess whether the described process will consistently produce a product meeting specifications. Process parameters that are not adequately controlled, or critical steps that are described vaguely, generate reviewer questions. The applicant should identify Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) explicitly, linking them through a coherent quality risk management framework aligned with ICH Q8 and Q9.<\/p>\n\n\n\n

    Stability Data<\/h4>\n\n\n\n

    Stability data must support the proposed shelf life for the drug product. For most applications, real-time data at the proposed storage condition (typically 25 degrees C \/ 60 percent RH) and accelerated data at 40 degrees C \/ 75 percent RH are required, following ICH Q1A guidelines. FDA requires at least 12 months of real-time data at submission for a new ANDA, with a commitment to continue stability through the full proposed shelf life.<\/p>\n\n\n\n

    Stability data must be generated on batches manufactured using equipment and processes representative of the commercial scale process. Data from laboratory-scale batches using different manufacturing equipment is generally not acceptable for commercial registration purposes. This requirement is straightforward in principle but operationally complex for manufacturers who do formulation development at pilot scale and must then scale up before generating registration stability batches.<\/p>\n\n\n\n

    Photostability testing under ICH Q1B is required for most drug products and should be conducted on the finished product in its final container closure system. Products that show photodegradation require either a protective container closure (opaque bottles, blister packaging with foil) or specific storage instructions on the label.<\/p>\n\n\n\n

    Module 5: Clinical Study Reports (Bioequivalence)<\/h3>\n\n\n\n

    For a standard ANDA, Module 5 contains the bioequivalence study reports. Each study report must include the protocol, protocol amendments, IRB approval, subject enrollment records, analytical method validation report, bioanalytical data, pharmacokinetic data, statistical analysis, and the final integrated report.<\/p>\n\n\n\n

    FDA’s bioanalytical guidance (Bioanalytical Method Validation, 2018) sets rigorous expectations for the validation of the analytical method used to measure drug concentrations in biological samples. Method validation must demonstrate accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the analyte in the biological matrix. A poorly validated bioanalytical method is one of the leading causes of complete response letters for ANDAs with bioequivalence data that would otherwise be acceptable.<\/p>\n\n\n\n

    The statistical analysis of bioequivalence data must use the standard two one-sided tests (TOST) procedure. The SAS or R code used for the statistical analysis should be provided, along with the raw pharmacokinetic data in an accessible format. FDA statistical reviewers do check the computations, and errors in the statistical analysis, even when the underlying data are sound, generate amendment requests.<\/p>\n\n\n\n

    The GDUFA Framework: What It Changed and What It Costs<\/h2>\n\n\n\n

    The Generic Drug User Fee Amendments of 2012 (GDUFA I) fundamentally changed the economics and timeline of ANDA review. Before GDUFA, FDA’s generic drug program was chronically underfunded, and ANDA review times stretched to three to five years in some cases. GDUFA established a user fee program that generated hundreds of millions of dollars annually for FDA to hire reviewers, clear the backlog, and establish target review timelines.<\/p>\n\n\n\n

    GDUFA II, reauthorized in 2017, refined the goal structure and added new commitments around facility inspection timelines and the review of complex drug applications. GDUFA III, currently in effect through fiscal year 2027, continued the evolution with additional performance goals, including specific commitments for the review of standard and priority applications.<\/p>\n\n\n\n

    User Fee Schedules<\/h3>\n\n\n\n

    ANDA applicants pay a user fee at the time of submission. The fee amount depends on the application type: full ANDA submissions, prior approval supplements, and certain types of amendments each carry different fee amounts. For fiscal year 2024, the standard ANDA user fee was approximately $243,000 [2]. This is not a small number for a mid-size generic manufacturer, and it makes the refuse-to-receive outcome particularly painful since the fee is not refunded when an application is rejected before filing.<\/p>\n\n\n\n

    Additionally, each pharmaceutical manufacturing facility that manufactures an approved generic drug product pays an annual facility fee. For fiscal year 2024, the domestic facility fee was approximately $313,000, and the foreign facility fee was approximately $327,000 [2]. Companies with multiple manufacturing sites across a portfolio of generics carry substantial cumulative GDUFA fee obligations.<\/p>\n\n\n\n

    FDA’s small business definition for user fee waiver purposes is a company with fewer than 500 employees that has not had an application approved in the prior three years. The waiver is available for the first application from such a company. Given that most companies filing ANDAs have approved applications, few qualify for the waiver, but it is worth verifying eligibility before assuming full fees are owed.<\/p>\n\n\n\n

    The 10-Month Review Clock<\/h3>\n\n\n\n

    Under GDUFA III, FDA’s goal is to act on 90 percent of standard ANDA submissions within 10 months of receipt, and on 90 percent of priority submissions within 8 months. ‘Acting’ on an application means issuing either an approval, a tentative approval, or a complete response letter. The goal is not approval within 10 months; it is a regulatory action within 10 months.<\/p>\n\n\n\n

    Priority review designation under GDUFA is available for ANDAs that address a drug shortage or that are for a product without an existing approved generic. Manufacturers pursuing priority designation should submit a complete and well-documented request with the application.<\/p>\n\n\n\n

    The 10-month clock starts on the date the application is received by FDA, not the date it is accepted for filing. FDA has 60 days to refuse to receive or to acknowledge receipt and begin formal review. Applications that pass the filing check and are not refused enter the standard review queue.<\/p>\n\n\n\n

    Controlled Correspondence as a Pre-Filing Tool<\/h4>\n\n\n\n

    FDA’s controlled correspondence program allows generic manufacturers to submit specific questions to the Office of Pharmaceutical Quality or the Office of Generic Drugs before filing an ANDA. Controlled correspondences are appropriate for questions about acceptable reference standards, bioequivalence study designs for drugs without published product-specific guidance, acceptable manufacturing sites, and container closure system suitability questions.<\/p>\n\n\n\n

    A well-crafted controlled correspondence can resolve a question that would otherwise generate a complete response letter 10 months after submission. The turnaround for a controlled correspondence is typically three to six months, which is far faster than the alternative. Any ANDA program targeting a drug with significant scientific or regulatory complexity should plan for at least one controlled correspondence before submitting the application.<\/p>\n\n\n\n

    Refuse-to-Receive and Complete Response Letters<\/h2>\n\n\n\n

    FDA has two formal mechanisms for rejecting ANDA submissions: the refuse-to-receive (RTR) decision and the complete response letter (CRL). They operate at different points in the process and have different implications.<\/p>\n\n\n\n

    Common RTR Triggers<\/h3>\n\n\n\n

    A refuse-to-receive decision means FDA has determined that the application is so fundamentally deficient that formal review cannot begin. The application is returned to the applicant with an explanation of the deficiencies, and the user fee is not refunded. The most common triggers for RTR decisions include:<\/p>\n\n\n\n

      \n
    • Missing or incomplete patent certifications for one or more Orange Book-listed patents<\/li>\n\n\n\n
    • Failure to provide bioequivalence data or a scientific justification for waiving in vivo studies when a waiver is not obviously applicable<\/li>\n\n\n\n
    • The proposed RLD has been withdrawn from the market for safety or effectiveness reasons<\/li>\n\n\n\n
    • Missing required environmental assessment or claim of categorical exclusion<\/li>\n\n\n\n
    • Incomplete 356h form or missing required certifications on the form<\/li>\n\n\n\n
    • Application submitted without meeting the eCTD technical formatting requirements<\/li>\n<\/ul>\n\n\n\n

      FDA’s refuse-to-receive checklist is publicly available, and applicants should use it as a literal pre-submission checklist, not merely as background reading. A qualified regulatory affairs professional should conduct a formal internal filing review against this checklist within the two weeks before submission.<\/p>\n\n\n\n

      Responding to a Complete Response Letter<\/h3>\n\n\n\n

      A complete response letter means FDA has reviewed the application but cannot approve it in its current form. The CRL lists the deficiencies that must be addressed. Unlike an RTR decision, a CRL is not a rejection of the application; it is a request for additional information or correction of deficiencies.<\/p>\n\n\n\n

      The response to a CRL is called a CRL response or a major amendment. It resets the review clock, typically to six months for a complete response to a major amendment under GDUFA goals. Partial responses, or responses that address some but not all deficiencies, are almost always counterproductive because they generate a second CRL.<\/p>\n\n\n\n

      A good CRL response does four things: it addresses every deficiency listed in the CRL explicitly, it provides cross-references to the specific sections of the submission where each deficiency is addressed, it does not introduce new issues that will trigger new questions, and it anticipates the next round of questions that the CRL response itself might generate.<\/p>\n\n\n\n

      Chemistry-Related CRL Issues<\/h4>\n\n\n\n

      Chemistry, manufacturing, and controls deficiencies are the most common CRL trigger. Typical CMC CRL issues include inadequate process validation, specifications that are not adequately justified by batch data, stability data that does not cover all relevant storage conditions, incomplete analytical method validation, and container closure systems that have not been demonstrated adequate for their intended purpose.<\/p>\n\n\n\n

      When a CRL identifies CMC deficiencies, the response typically requires additional experimental work. That experimental work takes time: a new stability study, additional process validation batches, or a revised analytical method validation can add six to eighteen months to the program timeline, depending on the nature of the deficiency. Early detection of CMC weaknesses, either through internal quality review or a pre-submission regulatory consultation, is worth far more than any savings from rushing to submit an undercooked application.<\/p>\n\n\n\n

      Bioequivalence-Related CRL Issues<\/h4>\n\n\n\n

      Bioequivalence CRL issues fall into two categories: study design problems, where FDA concludes the study was not designed to adequately test bioequivalence, and statistical problems, where the data show the product is not bioequivalent. The former can sometimes be remedied with a supplemental study using a revised design. The latter typically requires reformulation followed by a new bioequivalence study.<\/p>\n\n\n\n

      Failed bioequivalence is not necessarily the end of an ANDA program. If the failure is driven by a formulation issue rather than an inherent characteristic of the molecule, reformulation and a repeat study may bring the application back on track. The commercial question is whether the time and cost of reformulation and repeat bioequivalence testing still leave the program economically viable given the competitive timeline.<\/p>\n\n\n\n

      Paragraph IV Litigation: What Happens After You Certify<\/h2>\n\n\n\n

      Paragraph IV litigation is the adversarial process by which brand manufacturers challenge generic Paragraph IV ANDAs in federal court. Understanding the litigation dynamic is essential for any regulatory affairs team supporting a Paragraph IV filing, because the litigation directly affects the timeline, the label, and ultimately the commercial launch strategy.<\/p>\n\n\n\n

      The Mechanics of Paragraph IV Litigation<\/h3>\n\n\n\n

      When a generic applicant files a Paragraph IV certification, it must notify both the patent owner and the NDA holder within 20 days of FDA’s filing acceptance. The notice must be sent to specific individuals identified in FDA regulations and must include a detailed statement of the factual and legal basis for the Paragraph IV certification, commonly called the ‘detailed statement’ or ‘P4 letter.’ The detailed statement is a critical legal document that effectively limits the scope of the generic applicant’s invalidity and non-infringement positions in any subsequent litigation.<\/p>\n\n\n\n

      If the patent owner or NDA holder sues within 45 days, the 30-month stay begins. If they do not sue within 45 days, FDA can grant final approval immediately if all other conditions are met. Brand manufacturers almost always sue within the 45-day window if they believe the patent has any commercial value worth protecting.<\/p>\n\n\n\n

      The litigation itself is patent litigation, subject to the Federal Rules of Civil Procedure and the specialized rules of the District of Delaware, the District of New Jersey, and the Eastern District of Virginia, which together handle the majority of Hatch-Waxman cases. The technical complexity is high: judges and juries must understand both the chemistry or biology of the drug product and the legal standards for patent validity and infringement, including claim construction, anticipation, obviousness, and written description requirements.<\/p>\n\n\n\n

      180-Day Exclusivity: Who Gets It and Who Loses It<\/h3>\n\n\n\n

      The first generic applicant to file a substantially complete ANDA with a Paragraph IV certification for a given listed patent is entitled to 180 days of market exclusivity once it begins commercial marketing. During this 180-day window, FDA cannot grant final approval to any other ANDA for the same drug product with the same Paragraph IV certification for that patent. This exclusivity period is the most financially valuable prize in the generic drug industry.<\/p>\n\n\n\n

      The commercial value of 180-day exclusivity depends entirely on the drug. For a high-volume branded product with no other generic competition, the first filer may capture 70 to 90 percent of the market during the exclusivity window, at prices significantly above those in fully genericized markets. For a drug where multiple brand-name products exist, or where the patent being challenged is not the dominant IP barrier, the value is lower.<\/p>\n\n\n\n

      The exclusivity can be forfeited under several scenarios defined in the MMA. The most consequential forfeiture trigger is the failure-to-market provision: if a first-filer receives final approval but does not begin commercial marketing within 75 days of the later of FDA’s final approval or a court decision resolving the patent litigation, the exclusivity is forfeited. This provision was designed to prevent first filers from banking exclusivity as a competitive weapon without actually entering the market.<\/p>\n\n\n\n

      The ‘failure to obtain tentative approval within 30 months’ forfeiture trigger is also significant. If a first filer’s application has not received at least tentative approval within 30 months of submission, the exclusivity is forfeited unless the delay is directly caused by the 30-month stay itself. This provision penalizes applicants who file for Paragraph IV status but have deficient applications that cannot achieve even tentative approval within the standard timeframe.<\/p>\n\n\n\n

      Inter Partes Review as a Strategic Tool<\/h3>\n\n\n\n

      Inter partes review (IPR), introduced by the America Invents Act of 2011, allows any party to challenge the validity of a granted patent before the Patent Trial and Appeal Board (PTAB) on grounds of prior art. IPR has become a powerful tool for generic manufacturers because it can move faster than Hatch-Waxman district court litigation and, if successful, invalidates the patent entirely rather than just finding non-infringement.<\/p>\n\n\n\n

      A successful IPR petition that results in patent cancellation eliminates the listed patent and the associated 30-month stay. If a first-filer generic wins at PTAB and cancels the patent, all other ANDA applicants with Paragraph IV certifications against that patent can receive final approval without waiting for the first-filer’s 180-day exclusivity to expire, because the patent forfeiture provision in ANDA exclusivity law is triggered by certain court decisions and PTAB cancellations.<\/p>\n\n\n\n

      The strategic interplay between IPR and Hatch-Waxman litigation has created a complex ecosystem. Brand manufacturers routinely patent their products in ways designed to survive IPR challenges, and generic manufacturers’ IPR practice groups have become essential components of the ANDA pipeline.<\/p>\n\n\n\n

      Manufacturing Compliance: The cGMP Obligation That Never Ends<\/h2>\n\n\n\n

      FDA approval of an ANDA does not authorize a generic manufacturer to produce and sell drugs. It authorizes a specific facility, using a specific manufacturing process, to produce and sell the specific product described in the approved application. The manufacturing facility must comply with current Good Manufacturing Practice regulations at all times, and FDA can and does conduct inspections to verify compliance.<\/p>\n\n\n\n

      Pre-Approval Inspections<\/h3>\n\n\n\n

      Before granting final approval to an ANDA, FDA typically inspects the manufacturing facility to verify that the facility can actually produce the product as described in the application. Pre-approval inspections (PAIs) are supposed to be unannounced, though in practice FDA often has a general schedule.<\/p>\n\n\n\n

      An Official Action Indicated (OAI) classification from a PAI is a review-stopper. FDA will not approve the ANDA until the facility’s cGMP deficiencies are corrected and FDA verifies the correction, either through a re-inspection or through documented evidence that the issues have been resolved. The time from OAI classification to resolution varies from a few months for minor issues to two or more years for systemic quality problems.<\/p>\n\n\n\n

      Preventing a bad PAI outcome requires genuine quality system maturity, not just preparedness theater. Facilities that conduct regular internal mock inspections using FDA inspection protocols, that investigate out-of-specification results rigorously rather than minimally, and that have robust corrective and preventive action (CAPA) systems consistently perform better in PAIs than facilities that treat compliance as a periodic audit exercise.<\/p>\n\n\n\n

      Data Integrity: The Dominant cGMP Issue of the Last Decade<\/h4>\n\n\n\n

      Data integrity failures have been the leading cause of Warning Letters and import alerts for pharmaceutical manufacturing facilities over the past decade, affecting both domestic and foreign facilities. FDA’s data integrity expectations, set out in the 2016 and 2018 guidance documents on data integrity and cGMP, require that all raw data be attributable, legible, contemporaneous, original, and accurate (the ALCOA framework).<\/p>\n\n\n\n

      Common data integrity violations include deleting or overwriting chromatography runs that fail specification before they are formally recorded, backdating records, sharing login credentials, and failing to document all laboratory investigations. These violations, when found during inspection, are treated as serious systemic quality failures rather than individual documentation errors.<\/p>\n\n\n\n

      A data integrity finding in a PAI can affect not just the ANDA under review but the facility’s entire portfolio of approved products. FDA has broad authority to refuse to review new applications and to issue import alerts affecting all products from a facility where data integrity violations have been found.<\/p>\n\n\n\n

      Post-Approval Surveillance<\/h3>\n\n\n\n

      Once an ANDA is approved and the product is marketed, the manufacturer’s cGMP obligations do not diminish. FDA conducts periodic surveillance inspections of approved facilities, and manufacturers must report any significant chemistry, manufacturing, or controls changes through prior approval supplements (PAS) or changes being effected (CBE) filings before implementing those changes commercially.<\/p>\n\n\n\n

      The post-approval change management regulations under 21 CFR Part 314 define three tiers of change based on their potential to affect product quality: major changes (requiring prior approval), moderate changes (requiring a CBE-30 supplement filed 30 days before distribution), and minor changes (requiring an annual report). Implementing a change without the appropriate reporting can result in adulteration findings and product recalls.<\/p>\n\n\n\n

      Annual Product Reviews (APRs), or Product Quality Reviews (PQRs) as they are called under ICH Q10, are required for all approved products and must include a review of all batches produced, all out-of-specification results and investigations, all customer complaints, all stability data, and any trend analysis indicating a developing problem. Well-structured APRs that actually identify and address trends are a sign of a quality culture. APRs that are generated primarily to check a compliance box rarely catch developing quality problems before they become regulatory events.<\/p>\n\n\n\n

      The Complete ANDA Approval Checklist<\/h2>\n\n\n\n

      What follows is a structured checklist organized by phase. It is not exhaustive and does not substitute for qualified regulatory counsel, but it captures the most common points of failure and should be used as a working document by regulatory project teams.<\/p>\n\n\n\n

      Phase 1: Product Selection and Strategic Assessment<\/h3>\n\n\n\n
        \n
      1. Identify the RLD from the current Orange Book, confirm it has not been withdrawn for safety or efficacy reasons, and note all patent and exclusivity information.<\/li>\n\n\n\n
      2. Use DrugPatentWatch or an equivalent patent intelligence tool to review all listed patents, their expiration dates, and any existing Paragraph IV litigation history.<\/li>\n\n\n\n
      3. Download and review FDA’s product-specific guidance (PSGD) if one exists for the target RLD. If no PSGD exists, identify closely analogous products or plan a controlled correspondence.<\/li>\n\n\n\n
      4. Determine the appropriate patent certification strategy (Paragraph II, III, or IV) for each listed patent. Engage IP counsel early, not after the formulation is locked.<\/li>\n\n\n\n
      5. Evaluate whether a skinny label strategy is viable if method-of-use patents are listed. Assess the GlaxoSmithKline v. Teva risk before committing to a carve-out approach.<\/li>\n\n\n\n
      6. Confirm API sourcing and verify the DMF holder’s current FDA inspection status and any pending DMF deficiency letters.<\/li>\n\n\n\n
      7. Model the commercial case: first-filer exclusivity potential, competitive filing landscape, patient population size, and price erosion assumptions.<\/li>\n<\/ol>\n\n\n\n

        Phase 2: Formulation Development and Bioequivalence Planning<\/h3>\n\n\n\n
          \n
        • Design formulation to match RLD dissolution profile across multiple pH conditions and in both fed and fasted states where applicable.<\/li>\n\n\n\n
        • Identify whether the drug substance qualifies for a BCS biowaiver. If so, complete the solubility and permeability characterization per FDA’s 2017 BCS biowaiver guidance.<\/li>\n\n\n\n
        • If in vivo bioequivalence is required, select a CRO with FDA experience and verify their regulatory track record for the specific dosage form.<\/li>\n\n\n\n
        • Assess whether the drug is highly variable. If so, design the bioequivalence study to use the scaled average bioequivalence approach if FDA’s PSGD indicates this is appropriate.<\/li>\n\n\n\n
        • For NTI drugs, consult with FDA via controlled correspondence before finalizing the study protocol. Do not assume the standard 80 to 125 percent window applies.<\/li>\n\n\n\n
        • Finalize the meal composition for fed-state bioequivalence studies per FDA’s guidance and document the meal specification in the study protocol.<\/li>\n\n\n\n
        • Conduct a pre-study analytical method validation for the bioanalytical method to be used in the bioequivalence study. Cross-check against FDA’s 2018 bioanalytical method validation guidance.<\/li>\n<\/ul>\n\n\n\n

          Phase 3: CMC Development<\/h3>\n\n\n\n
            \n
          1. Define Critical Quality Attributes (CQAs) for the drug product based on the intended route of administration, dosage form, and product performance requirements.<\/li>\n\n\n\n
          2. Map Critical Process Parameters (CPPs) to CQAs through a structured risk assessment. Document the risk assessment per ICH Q9 principles.<\/li>\n\n\n\n
          3. Generate batch records for at least three registration stability batches at a scale representative of commercial production. Do not use laboratory-scale batches for registration stability.<\/li>\n\n\n\n
          4. Initiate long-term stability studies at ICH Zone II conditions (25 C \/ 60 percent RH) and accelerated conditions (40 C \/ 75 percent RH) simultaneously. Do not delay initiation to wait for formulation finalization.<\/li>\n\n\n\n
          5. Complete analytical method validation for all specification tests, including identity, assay, related substances, dissolution, water content, and any specific tests for the dosage form.<\/li>\n\n\n\n
          6. Verify container closure suitability through appropriate extractables\/leachables testing if applicable to the dosage form.<\/li>\n\n\n\n
          7. Conduct photostability testing per ICH Q1B on the final drug product in its final container closure system.<\/li>\n\n\n\n
          8. Confirm API specifications are aligned with the DMF and have been set based on batch data rather than solely on compendial limits.<\/li>\n<\/ol>\n\n\n\n

            Phase 4: Dossier Compilation and Pre-Submission Review<\/h3>\n\n\n\n
              \n
            • Verify the current Orange Book listing for the RLD on the business day before submission. Check for any new patent listings that may require additional certifications.<\/li>\n\n\n\n
            • Complete the 356h form accurately for all proposed strengths, dosage forms, and routes of administration.<\/li>\n\n\n\n
            • Prepare Paragraph IV notice letters for all relevant patents if filing a Paragraph IV ANDA. Engage IP counsel to review the detailed statement before submission.<\/li>\n\n\n\n
            • Confirm the ANDA user fee payment is scheduled for the submission date. FDA will not accept the application without fee payment confirmation.<\/li>\n\n\n\n
            • Conduct an internal filing review against FDA’s current refuse-to-receive checklist. Assign a qualified regulatory professional to this review, not the author of the dossier.<\/li>\n\n\n\n
            • Verify the eCTD formatting of the submission against FDA’s current eCTD specification. Run the submission through FDA’s validation software if available.<\/li>\n\n\n\n
            • Prepare the environmental assessment or claim of categorical exclusion. Most standard generic drug products qualify for a categorical exclusion, but the basis must be stated explicitly.<\/li>\n\n\n\n
            • Prepare a complete Module 2 quality overall summary that accurately reflects the Module 3 content and proactively addresses likely reviewer questions.<\/li>\n<\/ul>\n\n\n\n

              Phase 5: Post-Submission Management<\/h3>\n\n\n\n
                \n
              • Confirm receipt of FDA filing notification within 60 days of submission. If not received, contact FDA to verify the submission was received and is under filing review.<\/li>\n\n\n\n
              • Send Paragraph IV notice letters within 20 days of FDA’s filing acceptance, not 20 days of submission. Track the 45-day litigation window carefully.<\/li>\n\n\n\n
              • Monitor the review clock. If the 10-month goal date is approaching without communication from FDA, inquire through the ANDA status system.<\/li>\n\n\n\n
              • Respond promptly to any information requests (IRs) during review. FDA issues IRs for specific questions that do not rise to the level of a CRL. Delayed responses extend the review timeline.<\/li>\n\n\n\n
              • If a CRL is received, conduct a thorough cross-functional analysis before drafting the response. Do not rush the response. A CRL response that introduces new deficiencies is worse than a delayed response.<\/li>\n\n\n\n
              • Track the manufacturing facility inspection calendar. If a PAI is pending, ensure the facility is in full cGMP compliance and has addressed any observations from the most recent internal audit.<\/li>\n\n\n\n
              • For first-filer ANDAs, model the 75-day failure-to-market window. Have launch readiness plans in place so commercial marketing can begin within the forfeiture window once final approval is received.<\/li>\n<\/ul>\n\n\n\n

                Special Situations: Complex Dosage Forms, Hybrid Applications, and 505(b)(2)<\/h2>\n\n\n\n

                The standard ANDA pathway works well for oral solid dosage forms with straightforward pharmacokinetics. Many commercially valuable drugs do not fit that profile. Inhalation products, nasal sprays, transdermal systems, ophthalmic solutions, complex injectables, and topical products all present additional scientific, regulatory, and manufacturing challenges that significantly increase the complexity of the ANDA program.<\/p>\n\n\n\n

                Inhalation Products: Metered-Dose Inhalers and Dry Powder Inhalers<\/h3>\n\n\n\n

                Generic inhalers represent some of the most technically challenging ANDAs ever submitted. FDA’s approach to bioequivalence for locally acting pulmonary drug products requires that the generic product demonstrate equivalence not just in systemic exposure but in local drug delivery to the lung. For metered-dose inhalers, this requires an extensive in vitro characterization program including aerodynamic particle size distribution testing, plume geometry, spray content uniformity, and device resistance studies, along with in vivo pharmacokinetic and pharmacodynamic studies in most cases.<\/p>\n\n\n\n

                The first generic albuterol metered-dose inhaler, Perrigo’s ProAir HFA generic, received approval in 2020 after years of regulatory development, illustrating how long complex dosage form ANDAs can take even when the applicant is fully committed to meeting FDA’s requirements. The regulatory pathway for complex inhalers is now better defined than it was a decade ago, but it remains labor-intensive and expensive.<\/p>\n\n\n\n

                Dry powder inhalers present additional complexity because device performance is inseparable from drug delivery performance. A generic DPI ANDA requires not just bioequivalent drug delivery but a device that produces comparable performance characteristics to the RLD device across the relevant range of inspiratory flow rates. For products like Advair Diskus, this has required generic applicants to develop their own inhaler devices that can match the reference device’s performance without copying its design.<\/p>\n\n\n\n

                Transdermal Systems<\/h3>\n\n\n\n

                Transdermal patches present unique bioequivalence challenges because the rate-limiting step for drug delivery may be the skin rather than the formulation. For most transdermal products, FDA requires both in vivo pharmacokinetic bioequivalence studies and in vitro release rate testing. Residual drug content studies, to ensure that the generic patch delivers a comparable proportion of its total drug content over the labeled wear period, are also typically required.<\/p>\n\n\n\n

                Adhesion testing is a frequently overlooked requirement for transdermal ANDAs. FDA’s guidance on adhesion studies requires applicants to demonstrate that the generic patch maintains adhesion performance comparable to the reference product across the wear period. A patch that delivers the right amount of drug but falls off the skin is not bioequivalent in any clinically meaningful sense.<\/p>\n\n\n\n

                Complex Injectable Products<\/h3>\n\n\n\n

                Generic versions of liposomal injectables, microsphere depot formulations, and nanoparticle drug delivery systems present regulatory challenges that in some respects exceed those of complex inhalers. For liposomal products like liposomal doxorubicin (the generic of Doxil), FDA requires extensive physicochemical characterization of the liposomal particles, including particle size distribution, drug encapsulation efficiency, and membrane composition, in addition to pharmacokinetic bioequivalence.<\/p>\n\n\n\n

                The challenge is that physicochemical similarity is necessary but not sufficient to establish bioequivalence for complex injectable products. Two liposomal formulations can have identical particle size distributions and encapsulation efficiencies but different pharmacokinetic profiles if their membrane compositions or surface properties differ in ways that affect in vivo behavior. FDA’s approach to these products continues to evolve, and the PSGD for each complex injectable product should be reviewed carefully before committing to a development program.<\/p>\n\n\n\n

                NDA vs. ANDA: When 505(b)(2) Makes More Sense<\/h3>\n\n\n\n

                A 505(b)(2) application is a hybrid between an NDA and an ANDA. Like an ANDA, it can rely in part on FDA’s prior findings of safety and efficacy for a listed drug. Unlike an ANDA, it does not require pharmaceutical equivalence to the reference product and can seek approval for a different route of administration, dosage form, strength, or indication than the reference.<\/p>\n\n\n\n

                Generic manufacturers sometimes find that a 505(b)(2) pathway is commercially preferable to a full ANDA for products that have meaningful formulation differences from the RLD, or for products where the applicant is seeking a new indication that would add commercial value but is not covered by the listed patents. The 505(b)(2) pathway also allows greater flexibility in the bioequivalence approach, using clinical endpoint studies where pharmacokinetic studies are not appropriate.<\/p>\n\n\n\n

                The tradeoff is that 505(b)(2) applications are generally more expensive to develop than ANDAs, because they often require clinical data beyond standard bioequivalence studies. Whether the additional clinical investment is justified depends on the commercial case for the differentiated product.<\/p>\n\n\n\n

                ANDA Programs in a Global Context<\/h2>\n\n\n\n

                Most generic manufacturers who file ANDAs with FDA also seek approvals in other major markets. The strategic and operational interplay between ANDA programs and European Marketing Authorization Applications, Health Canada abbreviated applications, and emerging market dossiers creates both efficiencies and complications that deserve explicit attention in program planning.<\/p>\n\n\n\n

                The CTD Format as a Bridge<\/h3>\n\n\n\n

                The Common Technical Document format, which FDA requires for ANDAs through the eCTD gateway, is the same organizational framework used for pharmaceutical applications in the European Union, Canada, Japan, and most other advanced regulatory markets. This means that much of the analytical, stability, and manufacturing process documentation developed for an ANDA can be leveraged for other market submissions, with appropriate adaptation for local requirements.<\/p>\n\n\n\n

                The bioequivalence requirements, however, are market-specific and not interchangeable. An FDA-conducted bioequivalence study may not satisfy the EMA’s bioequivalence requirements if the statistical analysis or the subject population does not meet EMA’s standards. For cross-regional submissions, applicants should plan their bioequivalence programs to satisfy the most stringent applicable requirements, or plan for separate studies for different markets if the requirements are irreconcilably different.<\/p>\n\n\n\n

                API Supplier Qualification Across Markets<\/h3>\n\n\n\n

                An API supplier who has an active DMF with FDA may or may not have a valid European CEP or a WHO-prequalified product. For manufacturers who supply both FDA-regulated products and products for other markets, maintaining API qualifications across multiple regulatory frameworks requires dedicated supplier management resources. The consequences of a lapsed CEP or a failed WHO inspection can be as commercially damaging as an FDA import alert if the affected supplier accounts for a significant portion of the company’s API supply.<\/p>\n\n\n\n

                The ROI of Getting It Right the First Time<\/h2>\n\n\n\n

                The financial argument for investing in ANDA quality from the start is straightforward when the numbers are laid out.<\/p>\n\n\n\n

                “Generic drugs saved the U.S. health care system $408 billion in 2021 alone. Over the past decade, generic drug use has generated more than $2.9 trillion in savings.”<\/em> Association for Accessible Medicines, 2022 Generic Drug & Biosimilar Access & Savings in the U.S. Report [3]<\/p>\n\n\n\n

                Those savings flow through a system that rewards speed and penalizes deficiency-driven delays. A generic manufacturer who gets an ANDA approved in the first review cycle, without a CRL and without a PAI OAI classification, achieves market entry 10 to 24 months ahead of a competitor who cycles through one CRL and a repeat inspection. For a drug with $500 million in annual brand sales and a typical generic price erosion curve, those 10 to 24 months are worth between $50 and $200 million in revenue.<\/p>\n\n\n\n

                The costs of getting it wrong accumulate fast. A CRL response typically costs $500,000 to $2 million to prepare and submit, depending on the nature of the deficiencies. A repeat bioequivalence study can cost $1.5 to $5 million. A failed PAI followed by a consent decree-level remediation program can cost tens of millions of dollars across multiple years. None of these costs appear in the initial program budget because they were not anticipated, which makes them particularly damaging to companies operating on tight margins.<\/p>\n\n\n\n

                Where Generic Manufacturers Underinvest<\/h3>\n\n\n\n

                Across the ANDA lifecycle, there are two areas where generic manufacturers consistently underinvest relative to the return on that investment: pre-filing regulatory intelligence and post-submission dossier management.<\/p>\n\n\n\n

                Pre-filing regulatory intelligence, including patent landscape analysis, controlled correspondence, product-specific guidance review, and competitive filing research, is often treated as overhead rather than as a core commercial function. Tools like DrugPatentWatch exist precisely to reduce the cost of this intelligence work by consolidating patent expiration data, Orange Book listings, and litigation history in one place. Manufacturers who use these tools effectively identify both the opportunities (patents expiring in the near term with thin generic competition) and the risks (strong patent portfolios with active Paragraph IV litigation) before committing development resources.<\/p>\n\n\n\n

                Post-submission dossier management, meaning the active monitoring of the review clock, prompt responses to information requests, and proactive communication with FDA project managers, consistently differentiates manufacturers who move through review efficiently from those who experience unnecessary delays. FDA reviewers have large portfolios. Applications from sponsors who are responsive, organized, and whose submissions are clean consistently receive more efficient treatment than applications that are technically adequate but difficult to navigate.<\/p>\n\n\n\n

                Building an ANDA Pipeline: Portfolio Strategy<\/h3>\n\n\n\n

                The most successful generic manufacturers do not manage ANDAs as individual projects. They manage a pipeline with a portfolio logic: diversified across therapeutic categories to reduce concentration risk, timed across a multi-year horizon to smooth revenue peaks and valleys, and calibrated to the company’s manufacturing capabilities so that approved products can actually be manufactured profitably.<\/p>\n\n\n\n

                A healthy generic pipeline includes a mix of near-term revenue opportunities (Paragraph III filings for patents expiring in the next two to three years) and longer-term high-value opportunities (Paragraph IV filings against currently listed patents). The Paragraph IV pipeline requires more capital and carries more risk, but it generates the first-filer exclusivity opportunities that drive the most significant revenue events.<\/p>\n\n\n\n

                DrugPatentWatch’s patent expiration tracking, combined with FDA’s ANDA approval data (available through FDA’s Drugs@FDA database), allows manufacturers to identify which drug products have the fewest approved ANDAs and the closest patent expirations, representing the best opportunity for near-term market entry without Paragraph IV litigation risk. This kind of systematic pipeline development analysis, updated quarterly, is the foundation of a disciplined generic drug business.<\/p>\n\n\n\n

                Quality by Design: ICH Q8, Q9, Q10, and the Modern ANDA<\/h2>\n\n\n\n

                FDA formally adopted Quality by Design (QbD) principles through a series of International Council for Harmonisation guidelines, and while QbD is not mandatory for ANDA submissions, it is consistently rewarded in the review process. Applications that clearly articulate the design space, the edge of failure for critical process parameters, and the relationship between manufacturing variables and product quality give reviewers confidence that the manufacturer understands their product deeply.<\/p>\n\n\n\n

                The Quality Target Product Profile<\/h3>\n\n\n\n

                The Quality Target Product Profile (QTPP) is the starting point for a QbD-based ANDA. It defines the desired quality characteristics of the drug product, including the dosage form, route of administration, delivery system, dosage strength, pharmacokinetic attributes, and product quality criteria. The QTPP is not a specification; it is a design intent statement that guides formulation and process development.<\/p>\n\n\n\n

                In practice, many generic manufacturers use the approved RLD’s characteristics as a proxy for the QTPP. This is reasonable but incomplete: a thoughtfully constructed QTPP also captures attributes that the RLD may have but that the generic applicant has chosen not to replicate (such as certain excipients in the branded formulation that offer no advantage for the generic), as well as attributes that the applicant believes the RLD should have but does not specify.<\/p>\n\n\n\n

                Design Space and Regulatory Flexibility<\/h3>\n\n\n\n

                A design space is the multidimensional combination and interaction of input variables and process parameters that have been demonstrated to provide assurance of quality. Once FDA approves a design space in an ANDA, the manufacturer can operate anywhere within that space without filing a post-approval supplement. This provides regulatory flexibility that can save significant time and cost in the post-approval period when manufacturing conditions inevitably evolve.<\/p>\n\n\n\n

                Demonstrating a design space requires systematic experimentation, typically through Design of Experiments (DoE) studies, to characterize how the critical quality attributes respond to variation in input variables and process parameters. The investment in DoE during development pays dividends in regulatory flexibility for the life of the product.<\/p>\n\n\n\n

                Understanding FDA’s Office of Generic Drugs<\/h2>\n\n\n\n

                The Office of Generic Drugs (OGD) within FDA’s Center for Drug Evaluation and Research (CDER) is responsible for reviewing and approving ANDAs. OGD is organized into review divisions, each covering specific therapeutic areas or dosage form types. Understanding how OGD works, who the relevant contacts are, and how FDA communicates during the review process can meaningfully improve a manufacturer’s experience with the ANDA process.<\/p>\n\n\n\n

                Communication Channels During Review<\/h3>\n\n\n\n

                FDA’s primary mechanism for communicating with ANDA applicants during review is the information request (IR). An IR is a specific question or request for additional data that does not constitute a formal CRL. Responding to an IR promptly and completely is essential because unresolved IRs stop the clock on review progression.<\/p>\n\n\n\n

                For major scientific or regulatory questions, FDA may invite the applicant to a formal meeting. These meetings are requested through the standard CDER meeting request process and, when granted, allow direct dialogue between the applicant’s regulatory and scientific team and FDA reviewers. Meeting requests should be reserved for genuinely complex issues where written communication is unlikely to resolve the question efficiently.<\/p>\n\n\n\n

                FDA’s Generic Drug program also uses the Generic Drug Correspondence system, which allows applicants to submit formal questions and receive written responses outside of the formal review process. This system is appropriate for questions about existing approvals, guidance interpretations, and process clarifications, but should not be used as a substitute for resolving CRL deficiencies.<\/p>\n\n\n\n

                The Role of the Regulatory Project Manager<\/h3>\n\n\n\n

                Each ANDA is assigned a Regulatory Project Manager (RPM) within OGD who coordinates the review across the multiple disciplines involved (chemistry, pharmacology, biopharmaceutics, microbiology, and labeling). The RPM is the primary point of contact for the sponsor during review. Building a professional and organized relationship with the RPM, responding to their communications promptly, and providing organized and cross-referenced responses to information requests makes the review process more efficient for both parties.<\/p>\n\n\n\n

                Labeling: The Last Hurdle Many Teams Underestimate<\/h2>\n\n\n\n

                ANDA labeling must be the same as the approved RLD labeling, with specific exceptions. Generic applicants may omit brand name-specific information, replace the innovator’s company name and address with their own, and carve out method-of-use indications covered by patents under a section viii certification. Subject to these allowances, the labeling must be identical in content, though not necessarily identical in physical appearance.<\/p>\n\n\n\n

                Labeling Synchronization with RLD Updates<\/h3>\n\n\n\n

                Brand manufacturers update their labeling periodically based on post-marketing safety data, new clinical studies, or FDA-required labeling revisions. When the RLD label changes, approved generic manufacturers must update their labels to match. Failure to maintain labeling parity with the RLD is a cGMP violation and can result in enforcement action.<\/p>\n\n\n\n

                During the ANDA review process, if the RLD label changes between submission and approval, the applicant must update the proposed labeling to reflect the change before approval. FDA reviewers compare the proposed generic labeling to the current RLD labeling at the time of the labeling review, not the time of submission. Applicants should monitor the RLD’s labeling status through FDA’s DailyMed database throughout the review process.<\/p>\n\n\n\n

                SPL Formatting Requirements<\/h3>\n\n\n\n

                Generic drug labeling must be submitted in Structured Product Labeling (SPL) format, which is an XML-based format that FDA uses to populate its labeling database. SPL submission errors, including formatting errors, incorrect section codes, or missing required fields, generate labeling deficiencies that delay approval even when the underlying content is correct. Using a validated SPL authoring tool and conducting a technical review of the SPL file before submission avoids these preventable delays.<\/p>\n\n\n\n

                Key Takeaways<\/h2>\n\n\n\n
                  \n
                • The ANDA process rewards preparation. Every hour spent on pre-filing patent analysis, product-specific guidance review, and bioequivalence study design before committing development resources saves ten hours of CRL response work downstream.<\/li>\n\n\n\n
                • Patent certification is a legal and strategic decision, not just a regulatory box to check. Paragraph IV certifications should involve IP counsel and business development from the start, with detailed statements prepared carefully given their litigation implications.<\/li>\n\n\n\n
                • Tools like DrugPatentWatch give generic manufacturers a systematic view of patent expirations, Orange Book listings, and litigation history that is essential for prioritizing pipeline decisions and timing filings competitively.<\/li>\n\n\n\n
                • GDUFA changed the review timeline fundamentally. The 10-month review goal is real, but it requires a complete, high-quality application. A deficient application that cycles through one CRL adds 6 to 18 months to the approval timeline and often more in actual calendar time.<\/li>\n\n\n\n
                • CMC deficiencies are the leading cause of CRLs. Stability data, analytical method validation, process validation, and specification justification are the most common areas of weakness. Address them in the dossier before submission, not in response to a CRL.<\/li>\n\n\n\n
                • Data integrity is not a documentation formality. It is the foundation of the entire quality system. A data integrity finding in a PAI can affect every product from the facility, not just the ANDA under review.<\/li>\n\n\n\n
                • The 180-day exclusivity is the most financially significant prize in the generic industry, but it is also the most complex to preserve. Understanding the forfeiture provisions, particularly the failure-to-market provision, is essential for any company pursuing first-filer status.<\/li>\n\n\n\n
                • Post-approval compliance is ongoing. Label synchronization with the RLD, post-approval change management, and annual product quality reviews are not optional. They are the terms of the approval.<\/li>\n<\/ul>\n\n\n\n

                  FAQ<\/h2>\n\n\n\n

                  1. What is the difference between a refuse-to-receive decision and a complete response letter, and why does the distinction matter commercially?<\/h3>\n\n\n\n

                  A refuse-to-receive (RTR) decision is issued within 60 days of submission when FDA determines the application is so deficient that formal review cannot proceed. The application is returned, the user fee (approximately $243,000 in FY2024) is not refunded, and the applicant must prepare an entirely new submission. A complete response letter is issued after full review when FDA cannot approve the application in its current form but acknowledges that it is approvable in principle once deficiencies are corrected. The CRL response resets the review clock to a new goal date. Commercially, the RTR is more damaging because it effectively restarts the review clock entirely and consumes a full user fee. For a Paragraph IV applicant, an RTR can mean losing first-filer status to a competitor whose application, filed the same day, did not receive an RTR.<\/p>\n\n\n\n

                  2. How does the 30-month stay actually work when a brand manufacturer holds multiple patents listed in the Orange Book for the same drug?<\/h3>\n\n\n\n

                  Under the MMA of 2003, a brand manufacturer’s lawsuit within 45 days of notice of a Paragraph IV certification triggers a single 30-month stay per ANDA applicant, regardless of how many patents the brand manufacturer lists or how many lawsuits are filed. Before the MMA, brands routinely listed new patents close to generic filing dates to generate multiple consecutive stays. The post-MMA framework means that all listed patents must be addressed in the initial Paragraph IV certification, but only one 30-month stay applies. If a brand manufacturer successfully lists new patents after a generic application has been accepted, those new patents may require additional Paragraph IV certifications, but they do not generate additional automatic stays.<\/p>\n\n\n\n

                  3. When does filing a 505(b)(2) application make more sense than an ANDA, even for a product that is essentially a generic?<\/h3>\n\n\n\n

                  A 505(b)(2) makes more commercial sense than an ANDA when the product has a different dosage form, strength, route of administration, or indication than the approved RLD, when the bioequivalence standard for the ANDA pathway is practically impossible to meet with a product that differs meaningfully in formulation from the RLD, or when the applicant wants to use the differentiated product to establish a separate brand identity and brand-name exclusivity. The 505(b)(2) pathway is also appropriate when the active ingredient itself is approved but the specific combination or product configuration is novel enough that relying solely on the RLD’s safety and efficacy profile would be scientifically unsupported. The cost is higher because clinical endpoint studies or other additional data are typically required, but the commercial return can justify it when the differentiated product commands a premium price or avoids direct generic-to-generic competition.<\/p>\n\n\n\n

                  4. How should a generic manufacturer manage the 75-day failure-to-market window for 180-day exclusivity to avoid forfeiture?<\/h3>\n\n\n\n

                  The 75-day failure-to-market window starts from the later of: FDA’s final approval date, or the date of a court decision in the applicant’s favor resolving the patent litigation. From that date, the first filer must begin commercial marketing within 75 days or forfeit the 180-day exclusivity. Managing this window requires having commercial launch readiness in place before approval, not after. This includes: finished goods inventory at distribution centers, supply agreements with wholesalers, pricing decisions, sales force briefings if applicable, and legal clearance to begin commercial sales. For drugs where a 30-month stay is running and the launch date is predictable, companies can and should prepare for launch 12 to 18 months in advance. For drugs where a court decision creates an earlier-than-expected approval opportunity, companies need a rapid-deployment launch protocol that can execute within 75 days of an unexpected favorable decision.<\/p>\n\n\n\n

                  5. What does FDA actually look for in a Quality Overall Summary for an ANDA, and what makes a QOS weak?<\/h3>\n\n\n\n

                  FDA reviewers use the QOS as the primary navigation document for the CMC review. A good QOS tells the story of how the product was developed, why key decisions were made, what the risks are and how they are controlled, and where in Module 3 the supporting data can be found. A weak QOS either summarizes data without providing the scientific rationale for decisions, uses placeholder language that was not updated to reflect the actual development program, or fails to acknowledge limitations and explain how they were addressed. Reviewers who encounter a QOS that does not match Module 3 content, or that describes a different formulation than the one actually submitted, lose confidence in the entire dossier. The single most common QOS weakness is the disconnect between the development narrative and the actual registration batches, which happens when the QOS is written to describe the development program and is never updated to accurately reflect the commercial formulation used to generate registration stability data.<\/p>\n\n\n\n

                  References<\/h2>\n\n\n\n
                    \n
                  • [1] Association for Accessible Medicines. (2024). Generic drug & biosimilar access & savings in the U.S. annual report. Association for Accessible Medicines. https:\/\/accessiblemeds.org\/resources\/reports<\/li>\n\n\n\n
                  • [2] U.S. Food and Drug Administration. (2023). Generic drug user fee rates for fiscal year 2024. U.S. Department of Health and Human Services. https:\/\/www.fda.gov\/industry\/fda-user-fee-programs\/generic-drug-user-fee-amendments<\/li>\n\n\n\n
                  • [3] Association for Accessible Medicines. (2022). Generic drug & biosimilar access & savings in the U.S. 2022 report. Association for Accessible Medicines. https:\/\/accessiblemeds.org\/resources\/reports\/2022-generic-drug-biosimilar-access-savings-us-report<\/li>\n\n\n\n
                  • [4] U.S. Food and Drug Administration. (2018). Bioanalytical method validation guidance for industry. Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry<\/li>\n\n\n\n
                  • [5] U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/waiver-vivo-bioavailability-and-bioequivalence-studies-immediate-release-solid-oral-dosage-forms<\/li>\n\n\n\n
                  • [6] U.S. Food and Drug Administration. (2016). Data integrity and compliance with drug CGMP: Questions and answers. Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/data-integrity-and-compliance-drug-cgmp<\/li>\n\n\n\n
                  • [7] U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations (44th ed., Orange Book). U.S. Department of Health and Human Services. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book<\/li>\n\n\n\n
                  • [8] GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021), reh’g en banc denied, 23 F.4th 1347 (Fed. Cir. 2022).<\/li>\n\n\n\n
                  • [9] International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH. https:\/\/www.ich.org\/page\/quality-guidelines<\/li>\n\n\n\n
                  • [10] International Council for Harmonisation. (2021). ICH Q1A(R2): Stability testing of new drug substances and products. ICH. https:\/\/www.ich.org\/page\/quality-guidelines<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

                    A practical guide for regulatory affairs teams, IP counsel, and C-suite decision-makers The Stakes of the First Submission Every year, […]<\/p>\n","protected":false},"author":1,"featured_media":37003,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37001","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37001"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37001\/revisions"}],"predecessor-version":[{"id":37004,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37001\/revisions\/37004"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37003"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}